Generic Oncology Sterile Injectables Market to be Worth US$ 23.4 Billion by 2025 Globally

Published On : May 30, 2018

The global generic oncology sterile injectables market by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others) Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 9,838.0 million in 2017 and is projected to exhibit a CAGR of 11.4% over the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights. Availability of wide number of products for treatment of cancer, and ongoing research and development of different therapies is expected to fuel growth of the generic oncology sterile injectable market.

Teva Pharmaceutical Industries is focusing on generic pipeline that includes 330 product applications awaiting FDA approval in the U.S., including 71 tentative approvals till December 31, 2016. Pfizer in December 2016, entered into strategic collaboration with IGNITE Immunotherapy Inc. for discovery and development of targeted and next-generation intravenous oncolytic vaccines for cancer immunotherapy. According to Generics and Biosimilars Initiative, 2017, around 15 biosimilars of bevacizumab are in development. Moreover, Sandoz has leading biosimilar pipeline and plans to launch five biosimilar to treat oncology and immunology biologics by 2020. Baxter International, in 2017, entered into strategic partnership with ScinoPharm Taiwan Ltd. to develop, manufacture, and commercialize five injectables used in oncology treatments.

Browse 28 Market Data Tables and 25 Figures spread through 201 Pages and in-depth TOC on Generic Oncology Sterile Injectable Market by Product Type (Chemotherapy (Alkylating Agents, Antimetabolites, Plant Alkaloids, Antitumor Antibiotics, and Others) Monoclonal Antibodies, Cytokines, and Peptide Hormones), by Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and, Africa) - Global Forecast to 2025

To know the latest trends and insights prevalent in the generic oncology sterile injectables market, click the link below:

https://www.coherentmarketinsights.com/market-insight/generic-oncology-sterile-injectables-market-562

Key players in the market are focusing on strategic acquisitions, in order to enhance their market share. Pfizer, in 2014, acquired InnoPharma, which enabled them to acquire InnoPharma’s 10 U.S. FDA approved generic products and 19 pipeline and over 30 injectable products in development phase, which includes products for cancer and central nervous disorders. Pfizer, in 2016, acquired Medivation Inc. – a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Furthermore, Pfizer, Inc. acquired Hospira sterile injectables pharmaceuticals in 2015. Teva acquired the Allergan plc’s worldwide generic pharmaceuticals business (Actavis Generics) in 2016. Moreover, in 2016, Mylan completed acquisition of topical-focused business (both generic and specialty products) from Renaissance Acquisition Holdings, a contract manufacturing company. In 2015, Hikma Pharmaceuticals PLC acquired EIMC United Pharmaceuticals (EUP), a pharmaceutical manufacturing company specializing in oncology products.

Key Takeaways of the Generic Oncology Sterile Injectables Market:

  • The global generic oncology sterile injectables market is expected to exhibit a CAGR of 4% over the forecast period (2018–2026), owing to increasing product launches and robust pipeline.
  • Robust pipeline is expected to create a conducive environment for growth of the generic oncology sterile injectable market. For instance, 15 biosimilars of bevacizumab are in development as of 2017, according to Generics and Biosimilars Initiative.
  • The manufacturers such as Pfizer, Inc. are employing inorganic growth strategy to broaden its portfolio and sustain market competition
  • Major players operating in the generic oncology sterile injectables market include Amgen Inc., Teva Pharmaceutical Industries Ltd., Pfizer Inc., AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Sanofi S.A., Kissei Pharmaceutical Co. Ltd., AbbVie Inc., GlaxoSmithKline Plc, and Keryx Biopharmaceuticals Inc.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

Coherent Market Insights Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.